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LONG-LASTING ANTI-TUMOR IMMUNITY INDUCED BY THE REJECTION
OF DONOR HEMATOPOIETIC CELLS IN MIXED BONE MARROW CHIME-
RAS
Saito, T.I., Sykes, M. Massachusetts General Hospital/Harvard Medical
School, Boston, MA.
Background: Surprisingly, some patients who reject donor mar-
row grafts following nonmyeloablative HCT sustain remissions of
advanced hematological malignancies (Br J Haematol. 2005;128:
351). In murine mixed chimeras, we previously showed that recip-
ient leukocyte infusions (RLI) induced loss of donor chimerism and
anti-tumor responses against host-type tumors (Blood. 2003;102:
2300) and that T cells are necessary to achieve anti-tumor effects
(J Immunol. 2005;175:665). We now examined whether or not this
anti-tumor response demonstrates long-term memory. We at-
tempted to enhance anti-tumor effects by adding exogenous IL-15,
which promotes CD8 memory T cell survival. Methods: The A20
tumor model was used as previously described (Blood. 2003;102:
2300). Some groups received a secondary A20 challenge (105) 100
days after the ﬁrst challenge. Some groups received 5 g of IL-15
intraperitoneally, starting one week after RLI injection and every
12 h thereafter for a total of 10 doses. Spleen cells were isolated and
anti-tumor cytotoxicity was evaluated after 5 days’ coculture with
irradiated A20 cells. Results: One third of long-term survivors
(n  20) rejected a second lethal dose of A20 and survived 	200
days. In contrast, all mice in the control group that did not
previously receive RLI and received their ﬁrst tumor challenge
concurrently with the rechallenge group died, with a MST of 56
days (n  23) (P  .02). We have previously demonstrated in vitro
tumor-speciﬁc cytotoxic responses 11 weeks after ﬁrst tumor chal-
lenge. We now observed such responses even 11 months after ﬁrst
tumor challenge in some of the tumor survivors. From these
results, we speculated that memory CTL may play an important
role and hypothesized that exogenous IL-15 administration might
enhance the anti-tumor effect of RLI, since it promotes generation
and maintenance of memory T cells. Indeed, we observed in-
creased tumor-free survival in mice that received RLI and IL-15
(n  14) compared to recipients of RLI alone (n  14) (MST 64
versus 48 days respectively, P .03). Conclusion: Together, these
data suggest that RLI therapy can evoke long-term anti-tumor
immunity and that the anti-tumor response may be enhanced by
administration of exogenous IL-15, reinforcing the potential of
RLI therapy to provide a new HCT strategy lacking the risk of
graft-versus-host disease.
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COMPARISON OF 2 GVHD PROPHYLAXIS REGIMENS IN NONMYELO-
ABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (HSCT) WITH FLUDARABINE AND LOW DOSE TBI AS CONDITION-
ING: FAVORABLE OUTCOME WITH ADDITION OF SHORT COURSE OF
METHOTREXATE
Koh, L.-P.1, Tai, B.-C.2, Koh, M.B.C.1, Ng, H.-Y.3, Hwang, W.Y.K.1,
Linn, Y.-C.1, Goh, Y.-T.1, Fook Chong, S.M.C.4, Ng, H.-J.1,
Chuah, C.T.H.1, Loh, Y.S.M.1, Tan, D.C.L.1, Tan, P.H.C.5 1. De-
partment of Hematology, Singapore General Hospital, Singapore; 2.
Center for Molecular Epidemiology, Department of Community, Occu-
pational and Family Medicine, National University of Singapore, Sin-
gapore; 3. Department of Pharmacy, Singapore General Hospital, Sin-
gapore; 4. Department of Clinical Research, Singapore General Hospital,
Singapore; 5. Mount Elizabeth Hospital, Singapore.
The development of nonmyeloablative HSCT has extended the
potential curative treatment option of allografting to patients in
whom it was previously contraindicated due to advanced age or
comorbidity. Acute grade II-IV GVHD, albeit lower as compared
to ablative HSCT, causes substantial mortality and morbidity. In
this study, we investigated the effect of 2 GVHD prophylaxis
regimens on the incidence and severity of acute GVHD in 52
patients who received NM conditioning with ﬂudarabine 90
mg/m2 and TBI 2 Gy, followed by GCSF-mobilized peripheral
blood stem cell transplant from HLA identical (n  47), 5/6
antigen-matched related (n  2), or matched unrelated (n  3)
donors. Median age of these patients was 44 years (range; 20-60)
with 75% being 	40 years old. Diagnoses include leukemia/MDS
(n  38), lymphoma/myeloma (n  6), myeloﬁbrosis (n  1),
aplastic anemia (n 7). Twenty six (50%) patients were considered
to have good risk disease (CR1, CML in ﬁrst CP, aplastic anemia,
MDS-RA). Eight (16%) failed prior autologous (n  7) or alloge-
neic (n  1) HSCT. Twenty one patients received CSA and MMF
as GVHD prophylaxis (group 1), whereas 31 patients received
additional short course IV MTX (group 2). The 2 groups did not
differ signiﬁcantly in terms of age, gender, disease risk category,
CD34 cell dose, CD3 cell dose, duration of neutropenia and
thrombocytopenia. Median follow-up was 496 days and 101 days
for group 1 and 2, respectively. The cumulative incidence of grade
II-IV GVHD was 58% and 55% for group 1 and 2, respectively
(P  .93). The cumulative incidence of grade III-IV GVHD was
53% and 29% for group 1 and 2, respectively (P  .13). There was
no statistically signiﬁcant difference in the cumulative incidence of
relapse between the two groups (24% vs 54%; P .07). Transplant
related mortality (TRM) at 3 years was signiﬁcantly higher in
group 1 (71%) as compared to group 2 (16%) (P  .0001). The
difference in grade III-IV GVHD and TRM translate into a su-
perior 3-year overall survival (49% vs 5%; P  .001) and progres-
sion-free survival (30% vs 5%; P  .0015) in group 2 as compared
to group 1. Multivariate analysis identiﬁed the addition of MTX to
GVHD prophylaxis as the only factor that has signiﬁcant impact
on the overall and progression-free survival as well as TRM. In
conclusion, this retrospective study showed that modiﬁcation of
GVHD prophylaxis is crucial in reducing the incidence of severe
GVHD and TRM, resulting in favorable outcomes in patients
undergoing NMSCT.
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OCULAR GRAFT VS. HOST DISEASE EXPERIENCE FROM MD ANDERSON
CANCER CENTER: NEWLY DESCRIBED CLINICAL SPECTRUM AND NEW
APPROACH TO THE MANAGEMENT OF STAGE III AND IV OCULAR GVHD
Kim, S.K., Couriel, D., Ghosh, S., Champlin, R. UT MD Anderson
Cancer Center, Houston, TX.
Purpose: To describe new clinical entities associated with
chronic ocular GVHD and to describe new management of stage
III (pseudomembranous/membranous conjunctivitis) and IV ocular
GVHD (stage III plus corneal epithelial sloughing) from MD
Anderson Cancer Center (MDACC).Methods:Two retrospective
reviews of post-allogeneic BMT patients from MDACC Ophthal-
mology Clinic were performed 1) between 2003-2004 for acute and
chronic ocular GVHD and 2) between 2000-2002 for stage IV
ocular GVHD. Results: There were 194 patients with the diag-
nosis of acute or chronic ocular graft vs. host disease treated at MD
Anderson Cancer Center Ophthalmology Clinic between 2003-
2004. Among them, 2 cases of episcleritis and 14 cases of superior
limbic keratoconjunctivitis (SLK) were identiﬁed. Episcleritis is a
sectoral inﬂammatory condition of tissue between conjunctiva and
sclera with 1/3 association of systemic conditions, and SLK is
idiopathic, often bilateral, chronic conjunctival inﬂammatory pro-
cess with variable remission/exacerbation course. All 14 cases of
SLK were associated with Schirmer’s 	3 mm and cicatricial con-
junctival scarring of the upper lids. There were 17 patients with
stage III ocular GVHD with pseudomembranous/membranous
conjunctival ocular GVHD: 14 patients managed with extensive
lysis and removal of membrane/pseudomembrane plus topical ste-
roid and cyclosporine experienced less ﬁbrovascular scarring/cica-
tricial changes on the lids compared to 3 patients who were man-
aged conservatively with topical medication alone. Between 2000-
2002, there were 7 stage IV ocular GVHD patients. Early and
aggressive topical steroid lead to improved healing and decreased
corneal scarring (5/7) compared to those (2/7) treated with con-
servative treatment of topical antibiotic and lubrication alone.
Clinical ﬁndings of episcleritis and SLK in chronic GVHD and the
management of stage III and IV ocular GVHD have not been
previously described in the literature. Conclusions: Inﬂammatory
ocular conditions such as SLK and episcleritis may be observed as
clinical manifestations of chronic ocular GVHD. Our observation
suggests that the management of stage III and IV ocular GVHD
with aggressive topical steroid and the removal of inﬂammatory
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